Many polymer development partners are either bench-scale specialists who cannot deliver reproducible production volumes, or contract manufacturers who lack the synthetic chemistry depth to develop a polymer from scratch. The gap between the two is where most medical polymer programs stall. A polymer that works in a 1L flask does not necessarily work in a 25L reactor. A formulation that performs in development may not necessarily survive the regulatory requirements for clinical and commercial supply. The cost of finding out too late is measured in project delays, additional development work, and increased commercialization risk.
Polymer chemistries that work at laboratory scale often fail to translate to pilot or commercial batches. Without integrated process development, scale-up becomes a second project rather than a continuation of the first.
Many polymer development partners cannot deliver the quality systems, analytical methods, or documentation infrastructure required to support 510(k) submissions or GMP supply for clinical and commercial use.
Synthesis, scale-up, and manufacturing often involve three separate vendors. Each handoff adds technical transfer risk, qualification cycles, and lost institutional knowledge of the polymer and the monomer chemistry behind it.
Surmodics specialty polymer services, span custom synthesis, process development, scale-up, and contract manufacturing under one quality system. Customers engage Surmodics to solve complex polymer development, scale-up, and manufacturing challenges. The result is a characterized material, a reproducible manufacturing process, and a scalable supply strategy.
Functional polymer synthesis from concept through characterization, including hydrophilic, amphiphilic, bioabsorbable, and biostable chemistries engineered for medical applications. Monomer-level chemistry expertise applied across every program.
Process development and scale-up engineered for medical device and pharmaceutical use, bridging laboratory chemistry to pilot and commercial production with reproducible outcomes across reactor sizes.
Specialty contract manufacturing in cleanroom environments under appropriate controls, serving the medical device and pharmaceutical industries with established quality and regulatory infrastructure.
Over 50 years of experience supporting 510(k) cleared medical products, with the analytical depth, quality systems, and agile partnership approach to keep programs moving.
Surmodics is structured around four integrated service capabilities that move polymer programs from concept to commercial supply without changing partners. Customers engage at the stage that fits their program and stay through the stages that follow.
From a polymer idea to a characterized, reproducible material.
Customers come to Surmodics with an idea for a new polymer, a replacement for an existing polymer, or an improvement to a current material. Through custom polymer and monomer synthesis, the Surmodics team helps specify, develop, and characterize the polymer against the performance, regulatory, and manufacturing requirements of the application. Synthesis spans bioabsorbable polyesters, biostable copolymers, and modifications of natural biopolymers including agarose, cellulose, dextran, and alginate.
Built for:
Reproducible processes engineered for medical-grade production outcomes.
Successful commercialization requires more than a promising polymer chemistry. For medical applications, a proper process must be in place to yield reproducible production outcomes across scales. The Surmodics process development capability bridges the gap from laboratory chemistry to commercial production, with expertise spanning analytical method development, process simplification, solvent selection, scalable reactor design, and quality control method establishment.
Built for:
Pilot to commercial scale in cleanroom environments under medical-grade controls.
Surmodics offers contract manufacturing for the medical device and pharmaceutical industries, operating in cleanroom environments under appropriate controls for medical-grade polymer production. The Surmodics facility supports pilot batch scale-up greater than 100 kg batches or 4 tons per year, with eight flexible controlled rooms totaling 20,000 square feet supporting synthesis, isolation, purification, drying, milling, and sieving operations from pilot batch scale-up up greater than 100 kg batches.
Built for:
The data infrastructure to support a regulatory submission.
The Surmodics analytical laboratory is equipped to characterize polymer materials through every phase of development and manufacturing. Capabilities include HPLC, SEC for molecular weight determination, GC, FTIR, UV/VIS spectroscopy, rheometry, DSC, microscopy, and specialized inspection equipment for hydrogel material testing. Analytical methods are developed alongside the polymer chemistry, developed alongside the polymer and process development program.
Built for:
Integrated polymer development translates into outcomes that are difficult to assemble from separate providers.
Synthesis, process development, and manufacturing in one location eliminate the qualification cycles required to transfer a polymer program between vendors.
Monomers and polymers scaled across 1L, 4L, 10L, 25L, and pilot reactor sizes with consistent characterization, reducing the risk of scale-dependent performance changes.
Quality control methods, raw material oversight, and finished-goods release testing built into the manufacturing program from the start.
Surmodics is structured to combine technical expertise with responsive collaboration, supporting customer priorities through every phase of polymer development and production.
The polymer that performs in a 1L flask is rarely the polymer that performs in a 25L reactor. The chemistry stays the same. The mass transfer, the heat profile, the mixing dynamics, the impurity profile, the isolation step. All of it changes. The polymer that arrives at commercial scale is shaped as much by the process around it as by the synthetic chemistry itself.
This is why Surmodics engages at the synthesis stage and stays through manufacturing. Decisions made at the bench, about solvent system, about reagent feeding, about isolation method, determine what is possible at scale. The polymer programs that move fastest are the ones where the same team that designs the chemistry also designs the process and runs the production. Knowledge does not get lost in the transfer because there is no transfer.
Surmodics polymer programs are typically governed by customer confidentiality. The depth of the capability portfolio shows up consistently across three dimensions that shape medical and pharmaceutical polymer program outcomes.
Surmodics polymer programs routinely involve simplifying customer processes that were originally developed at bench scale with multi-step solvent operations, time-controlled reagent additions, or precipitation and re-dissolution requirements. The simplification work translates directly into improved reproducibility and reduced production cost at scale.
The Surmodics facility supports consistent polymer characterization across 1L, 4L, 10L, 25L, and pilot reactor vessels, with pilot batch capacity greater than 100 kg per batch or 4 tons per year. Scale transitions are engineered with analytical methods, including molecular weight determination via size exclusion chromatography, to verify consistency across reactor sizes.
Coating and testing equipment, ready to run.
Surmodics polymer programs operate at facilities that are either ISO 13485 certified or ISO 13485 and ISO 9001 certified. This includes analytical method development, raw material quality control, finished-goods release testing including rheological QC for hydrogel programs, and the documentation infrastructure required for medical device and pharmaceutical submissions. The quality system is built into the manufacturing program, not bolted on for audit.
Surmodics specialty polymer services are engineered for programs where custom chemistry, scaled production, and medical-grade quality infrastructure all need to come from the same source.
Organizations developing novel polymer chemistries requiring specification, synthesis, and characterization.
If you have an existing polymer that needs to be modified, improved, or replaced and scaled with a chemistry better suited to your application.
If you developed a polymer at laboratory scale and need a partner to scale the process to pilot or commercial volumes without losing reproducibility.
If you need a custom polymer manufactured under medical-grade quality systems with full analytical and regulatory documentation.
If you are developing a hydrogel, drug delivery polymer, or other medical or pharmaceutical material that requires specialized handling and characterization.
If you are managing multiple polymer vendors and want to consolidate synthesis, scale-up, and manufacturing under one partnership.
Custom polymer chemistry is only part of the answer. The companies that bring better polymer-enabled devices and pharmaceutical products to market faster are the ones working with a partner that brings synthesis, scale-up, manufacturing, and regulatory infrastructure to the same conversation.
Custom polymer synthesis across hydrophilic, amphiphilic, bioabsorbable, biostable, and natural-biopolymer chemistries, developed and characterized against the requirements of the specific application.
Engagement from initial synthesis through process development, scale-up, and commercial manufacturing, with quality and analytical infrastructure built into every phase.
Engagement at any stage of the polymer program, from concept synthesis to scaled commercial supply, with the agility to adjust as the program evolves.
Pilot batch capacity greater than 100 kg or 4 tons per year, supported by over 50 years of experience supporting 510(k)-cleared medical products and a quality system engineered for medical and pharmaceutical applications.
Surmodics engagement models are calibrated to where the polymer program is and where it needs to go. Customers engage at the stage that fits and stay through the stages that follow, with no technical transfer required between phases.
Concept-stage engagement focused on custom polymer specification, synthesis, and characterization. Engineered for programs that need a polymer designed against specific performance, regulatory, or manufacturing requirements.
Full-program engagement spanning synthesis, process development, and analytical method establishment. One team, one high quality standard, one partner from chemistry concept through reproducible production process.
Quality and regulatory engagement layered into every program. Analytical methods, raw material control, finished-goods release testing, and documentation infrastructure built for medical device and pharmaceutical submissions.
Commercial manufacturing engagement with cleanroom infrastructure, pilot batch capacity greater than 100 kg, and scaled production systems for clinical and commercial supply programs.
Whether you have an early-stage polymer idea, an existing polymer that needs scaled production, or a clinical-stage program ready to transition to commercial supply, Surmodics is built to engage at any stage of the program.
